XBiotech Inc. Files 8-K on Shareholder Vote Matters

TL;DR

XBiotech Inc. filed an 8-K on Aug 29th for a shareholder vote. Governance update.

AI Summary

XBiotech Inc. filed an 8-K on September 2, 2025, reporting on matters submitted to a vote of security holders as of August 29, 2025. The filing details the company's corporate structure, including its state of incorporation (British Columbia, Canada) and principal executive offices in Austin, Texas.

Why It Matters

This filing indicates that XBiotech Inc. held a shareholder vote, which is a key governance event that can impact corporate direction and shareholder rights.

Risk Assessment

Risk Level: low — This is a routine corporate filing related to a shareholder vote, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

• XBiotech Inc. (company) — Registrant
• August 29, 2025 (date) — Date of earliest event reported
• September 2, 2025 (date) — Date of Report
• British Columbia, Canada (location) — State of Incorporation
• Austin, TX (location) — Address of principal executive offices

FAQ

Filing Documents

• f8k_090225.htm (8-K) — 29KB
• 0001171843-25-005673.txt ( ) — 186KB
• xbit-20250829.xsd (EX-101.SCH) — 3KB
• xbit-20250829_lab.xml (EX-101.LAB) — 33KB
• xbit-20250829_pre.xml (EX-101.PRE) — 22KB
• f8k_090225_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The annual meeting of the stockholders of XBiotech Inc. (the "Company") was held on August 29, 2025. The matters that were voted upon at the meeting, and the number of votes cast for and against, as well as the number of abstentions and broker non-votes as to each such matter, are set forth below. Stockholders voted in accordance with the Board of Directors' recommendations on each matter and voted to (1) elect five nominees for director; (2) ratify the selection by the Audit Committee of the Board of Directors of Whitley Penn LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025;(3)approve, on an advisory basis, the compensation of the Company's named executive officers;(4) approve the Company's 2025 Equity Incentive Plan. Proposal #1 Election of five members of the Board of Directors For Abstain Broker Non-Votes John Simard 12,371,115 494,017 2,824,207 Thomas Kndig 12,698,614 166,518 2,824,207 Craig Rademaker 12,501,468 363,664 2,824,207 Tevi D. Troy 12,301,285 563,847 2,824,207 David Soffer 12,302,090 563,042 2,824,207 Proposal #2 Ratification of the selection of Whitley Penn LLP as the Company's independent registered public accounting firm for the fiscal year ending 2025 For Against Abstain Broker Non-Votes 15,206,712 413,673 68,954 0 Proposal #3 Advisory Vote on Executive Compensation For Against Abstain Broker Non-Votes 11,336,500 1,460,498 68,134 2,824,207 Proposal #4 Approval of the Company's 2025 Equity Incentive Plan For Against Abstain Broker Non-Votes 11,952,280 904,108 8,744 2,824,207

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 2, 2025 XBIOTECH INC. By: /s/John Simard John Simard Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR